This indicates that the interest in clinical applications of Nrf2 has recently expanded and culminated in the realization of clinical trials with Nrf2 pathway activators, including e.g., the use of sulforaphane-rich broccoli sprout extracts for detoxication of airborne pollutants [23,42] or for diabetes [25], bardoxolone methyl (CDDO-Me) for chronic kidney disease [27] and dimethyl-fumarate (BG-12) for multiple sclerosis [43]. The gene discussed is NFE2L2; the disease is diabetes mellitus.